Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


NextGen divests automation and software business

This article was originally published in Scrip

Executive Summary

NextGen Sciences, a US-based biomarker service provider, has sold its gene-to-protein automation and software business to eXeTek, a management-led spin-out from the company. The divestment is past of NextGen's plan announced in April to focus all resources on growing its protein biomarker services business. NextGen has acquired a 24% stake in eXeTek, which will be led by former employees Stephen Woodall and Stuart Hill, and will receive 5% royalties on sales for three years. NextGen's protein service portfolio, which it calls biomarker express, includes biomarker discovery and assay development and testing.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts